전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,092 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleDaniel LandiPhase 1

EGFRvIII CAR T cells (EGFRvIII CAR T cells)

Glioblastoma; Gliosarcoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleZhejiang UniversityPhase 1

EPCAM CAR-T (EPCAM CAR-T)

Advanced Hepatocellular Carcinoma; Advanced Colorectal Cancer · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

EPCAM-targeted CAR-T cells (EPCAM-targeted CAR-T cells)

Stomach Neoplasms · Liver Neoplasms

#LiverNeoplasms#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEutilexPhase 1

EU307 CAR-T Cell (EU307 CAR-T Cell)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Efficacy of LCAR-T2C CAR-T cells (Efficacy of LCAR-T2C CAR-T cells)

T Cell Lymphoma; T-cell Leukemia · T Cell Lymphoma

#TCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 1

Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells (Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells)

Difficult to Treat Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSolving Kids' CancerPhase 1

Ex vivo Expanded and Activated Haploidentical Donor NK Cells (Ex vivo Expanded and Activated Haploidentical Donor NK Cells)

Neuroblastoma; Relapsed Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleFundación de Investigación Biom…Preclinical

ustekinumab (Stelara, Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab)

Inflammatory Bowel Disease · Inflammatory Bowel Disease

#InflammatoryBowelDisease#Antibody#Preclinical#monoclonal-antibody#Fundacin
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

Expanded CB-NK cells (Expanded CB-NK cells)

Colon Cancer; Resected Stage · Colon Cancer

#ColonCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

FGFR4-CAR T Cells (FGFR4-CAR T Cells)

Rhabdomyosarcoma · Rhabdomyosarcoma

#Rhabdomyosarcoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleWashington Research FoundationPhase 1

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

Advanced Osteosarcoma; Recurrent Osteosarcoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

FOLR1 CAR T-cells (FOLR1 CAR T-cells)

Recurrent Childhood Acute Myeloid Leukemia; Refractory Childhood Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

37 / 55 pages

← PreviousNext →